Hyperfine, Inc.

What they do

Hyperfine develops and sells the Swoop Portable MR Imaging System, a portable ultra-low-field MRI device that produces brain images at a lower magnetic field than conventional MRI. The system is used across multiple care settings such as ICUs, emergency departments, and physician offices. It offers T1, T2, DWI, and FLAIR sequences, with a full brain scan averaging about 25 minutes. The company generates revenue primarily from system sales, supplemented by related accessories and services.

Revenue drivers

• Swoop system sales — Primary revenue source; the company sold 12 commercial systems in Q2 2026, up 50% from 8 in Q2 2025, and management expects full-year 2026 revenue of $20-$22 million.
• Software and AI (Optive AI) — Integrated AI software enhances image quality and is included with each system; no separate revenue detail is provided, but it supports recurring value and upgrades.
• International expansion — Recent CE Mark and UKCA approvals for the next-generation system, with initial European sales announced; helps diversify geographic revenue.

Recent performance

In Q2 2026, Hyperfine reported revenue of $3.9 million, up 44.8% year-over-year from $2.7 million. Gross margin improved to 50.7%, up from 49.3%; net loss was $9.3 million, or $0.09 per share, slightly deeper than the $9.2 million loss in Q2 2025. Cash and cash equivalents stood at $43.5 million at June 30, 2026, up from $35.1 million at year-end 2025, partly due to financing activities. Annual revenue grew from $1.5 million in 2021 to $13.6 million in 2025, with net losses narrowing to $35.6 million in 2025. Quarterly revenue in Q1 2026 was $3.9 million, roughly flat sequentially.

Strategy

Hyperfine is focused on expanding placements in hospital and neurology office settings, leveraging the next-generation Swoop system launched in 2025. It is broadening international reach, with CE Mark and UKCA approvals and initial European sales. The company is investing in clinical evidence, including the PRIME study and new publications, and has formed a Global Neurosurgery Advisory Council. Management emphasizes gross margin expansion, disciplined operating expenses, and cash burn reduction, targeting approximately $26-$28 million cash burn in 2026.

Risks

• Continued losses — The company has a history of net losses and an accumulated deficit of $330.0 million as of year-end 2025, with no guarantee of future profitability.
• Dependence on regulatory approvals — Recent CE Mark and UKCA approvals are critical for international growth, but any loss of approvals or new regulatory hurdles would harm operations.
• Market adoption uncertainty — The Swoop system is a new product category; broader clinical adoption across care settings is still evolving and may not materialize as expected.
• Competition and technology shifts — The portable MRI market is nascent, and traditional MRI vendors or new entrants could limit Hyperfine's market share and pricing power.

Outlook

Management expects full-year 2026 revenue of approximately $20-$22 million, implying about 55% growth at the midpoint over 2025. Cash burn for 2026 is forecast at $26-$28 million, a 10% decline at the midpoint. The company anticipates continued momentum in U.S. scan volumes and international progress toward mainstream clinical use.